PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

Phase 2

Terminated

Conditions: Postherpetic Neuralgia

Interventions: Drug: T-62 Dose 1
Drug: T-62 Dose 2
Other: Placebo

First Posted Date: 2008-12-17

Last Posted Date: 2012-06-08

Lead Sponsor: Pfizer

Target Recruit Count: 19

Registration Number: NCT00809679

The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)

Phase 3

Completed

Conditions: Community Acquired Pneumonia (CAP)

Interventions: Drug: Azithromycin

First Posted Date: 2008-12-17

Last Posted Date: 2011-05-19

Lead Sponsor: Pfizer

Target Recruit Count: 102

Registration Number: NCT00809328

Locations: 🇯🇵
Pfizer Investigational Site, Shiogama-city, Japan

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

Phase 3

Terminated

Conditions: Osteoarthritis
Arthritis

Interventions: Drug: NSAID
Biological: tanezumab

First Posted Date: 2008-12-17

Last Posted Date: 2021-06-24

Lead Sponsor: Pfizer

Target Recruit Count: 2720

Registration Number: NCT00809354

Locations: 🇺🇸
Perimeter Institute for Clinical Reseach, Inc., Atlanta, Georgia, United States
🇺🇸
Laureate Clinical Research Group, Atlanta, Georgia, United States
🇺🇸
Optimed Research, LTD, Columbus, Ohio, United States

and more 320 locations

Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers

Phase 1

Completed

Conditions: Fibromyalgia

Interventions: Drug: esreboxetine
Drug: placebo
Drug: moxifloxacin

First Posted Date: 2008-12-17

Last Posted Date: 2011-04-07

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT00809289

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Extension Study Of Tanezumab In Osteoarthritis

Phase 3

Terminated

Conditions: Osteoarthritis

Interventions: Biological: tanezumab

First Posted Date: 2008-12-17

Last Posted Date: 2021-05-10

Lead Sponsor: Pfizer

Target Recruit Count: 2147

Registration Number: NCT00809783

Locations: 🇺🇸
Laureate Clinical Research Group, Atlanta, Georgia, United States
🇺🇸
Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States
🇺🇸
Rehabilitation Institute of Chicago, Chicago, Illinois, United States

and more 215 locations

Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time

Phase 1

Terminated

Conditions: Generalized Anxiety Disorder

Interventions: Drug: PD 0332334
Drug: Metformin

First Posted Date: 2008-12-17

Last Posted Date: 2010-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00809536

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking

Completed

Conditions: Smoking Cessation

Interventions: Drug: varenicline

First Posted Date: 2008-12-15

Last Posted Date: 2015-05-12

Lead Sponsor: Pfizer

Target Recruit Count: 1373

Registration Number: NCT00808015

Locations: 🇵🇭
Pfizer Investigational Site, Quezon City, Philippines

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

Phase 2

Completed

Conditions: Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive

Interventions: Drug: PF-00610355
Drug: Salmeterol
Drug: PF- 00610355
Drug: Placebo
Drug: PF - 00610355

First Posted Date: 2008-12-15

Last Posted Date: 2019-02-06

Lead Sponsor: Pfizer

Target Recruit Count: 405

Registration Number: NCT00808288

Locations: 🇹🇷
Pfizer Investigational Site, Izmir, Turkey

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis
Menopause

Interventions: Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg
Drug: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg
Drug: bazedoxifene 20 mg
Drug: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg
Drug: Placebo

First Posted Date: 2008-12-15

Last Posted Date: 2014-04-08

Lead Sponsor: Pfizer

Target Recruit Count: 1886

Registration Number: NCT00808132

Locations: 🇵🇱
Pfizer Investigational Site, Wroclaw, Poland

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Phase 2

Completed

Conditions: Meningitis, Meningococcal

Interventions: Other: normal saline (placebo)
Biological: meningococcal B rLP2086 vaccine.

First Posted Date: 2008-12-15

Last Posted Date: 2015-04-14

Lead Sponsor: Pfizer

Target Recruit Count: 538

Registration Number: NCT00808028

Locations: 🇵🇱
ZOZ w Debicy, Poradnia Chorob Zakaznych, Debica, Poland
🇵🇱
SP ZOZ Krakowski Szpital Specjalistyczny im. Jana Pawla II w Krakowie, Krakow, Poland
🇵🇱
NZOZ Salmed, Leczna, Poland

and more 24 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy